Methamphetamine-induced sensitization is associated with alterations to the proteome of the prefrontal cortex: Implications for the maintenance of psychotic disorders

Journal of Proteome Research

Volumn 14, Issue 1, 2015, Pages 397-410

  Wearne, Travis A ^a   Mirzaei, Mehdi ^a   Franklin, Jane L ^a   Goodchild, Ann K ^b   Haynes, Paul A ^a   Cornish, Jennifer L ^a  

^a MACQUARIE UNIVERSITY   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

Author keywords

GABA; methamphetamine; mitochondrial function; nanoflow LC MS MS; prefrontal cortex; protein expression; Proteomics; psychosis; schizophrenia; synaptic proteins

Indexed keywords

CELL ADHESION MOLECULE; CLATHRIN LIGHT CHAIN; COP9 SIGNALOSOME; CYTOCHROME C OXIDASE; DIACYLGLYCEROL KINASE; FATTY ACID BINDING PROTEIN; GLUTAMATE DECARBOXYLASE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; GUANINE DEAMINASE; HEPATOMA DERIVED GROWTH FACTOR; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; LEUKOTRIENE A4 HYDROLASE; METHAMPHETAMINE; NUCLEOSIDE DIPHOSPHATE KINASE NM23; PALMITOYL COENZYME A HYDROLASE; PEPTIDYLPROLYL ISOMERASE; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2; PROHIBITIN; PROLINE IMINOPEPTIDASE; PROSTAGLANDIN E SYNTHASE; PROTEIN TYROSINE PHOSPHATASE; PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE COMPLEX; RECOMBINANT SOMATOMEDIN C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RIBOSOME PROTEIN; SORTING NEXIN; THIOSULFATE SULFURTRANSFERASE; PROTEOME;

ANIMAL EXPERIMENT; ARTICLE; BRAIN FUNCTION; CALCIUM CELL LEVEL; CELL DEATH; CELL FUNCTION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; INTRACELLULAR SIGNALING; LIQUID CHROMATOGRAPHY; LOCOMOTION; MALE; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PREFRONTAL CORTEX; PROTEIN EXPRESSION; PROTEOMICS; RAT; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; ANIMAL; BIOLOGICAL MODEL; CENTRAL NERVOUS SYSTEM SENSITIZATION; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DATABASE; PSYCHOSIS; SYNAPSE;

ANIMALIA; RATTUS; RODENTIA;

ANIMALS; CENTRAL NERVOUS SYSTEM SENSITIZATION; CHROMATOGRAPHY, LIQUID; DATABASES, PROTEIN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; MALE; METHAMPHETAMINE; MODELS, NEUROLOGICAL; PREFRONTAL CORTEX; PROTEOME; PSYCHOTIC DISORDERS; RATS; SYNAPSES; TANDEM MASS SPECTROMETRY;

EID: 84920276677     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr500719f     Document Type: Article

References (117)

1. Harvey, P. D.; Heaton, R. K.; Carpenter, W. T., Jr.; Green, M. F.; Gold, J. M.; Schoenbaum, M. Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation Schizophr. Res. 2012, 140, 1-8
2. Jablensky, A. Epidemiology of schizophrenia: the global burden of disease and disability Eur. Arch. Psychiatry Clin. Neurosci. 2000, 250, 274-285
3. Sharma, T.; Antonova, L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment Psychiatric Clin. North Am. 2003, 26, 25-40
4. Howes, O. D.; Kapur, S. The dopamine hypothesis of schizophrenia: version III-the final common pathway Schizophr. Bull. 2009, 35, 549-562
5. Laruelle, M. Schizophrenia: from dopaminergic to glutamatergic interventions Curr. Opin. Pharmacol. 2014, 14, 97-102
6. Keefe, R. S.; Harvey, P. D. Cognitive impairment in schizophrenia Handb. Exp. Pharmacol. 2012, 11-37
7. Leucht, S.; Arbter, D.; Engel, R. R.; Kissling, W.; Davis, J. M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials Mol. Psychiatry 2009, 14, 429-447
8. McKetin, R.; Hickey, K.; Devlin, K.; Lawrence, K. The risk of psychotic symptoms associated with recreational methamphetamine use Drug Alcohol Rev. 2010, 29, 358-363
9. McKetin, R.; McLaren, J.; Lubman, D. I.; Hides, L. The prevalence of psychotic symptoms among methamphetamine users Addiction 2006, 101, 1473-1478
10. Chen, C. K.; Lin, S. K.; Sham, P. C.; Ball, D.; Loh, E. W.; Hsiao, C. C.; Chiang, Y. L.; Ree, S. C.; Lee, C. H.; Murray, R. M. Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis Psychol. Med. 2003, 33, 1407-1414
11. Farrell, M.; Boys, A.; Bebbington, P.; Brugha, T.; Coid, J.; Jenkins, R.; Lewis, G.; Meltzer, H.; Marsden, J.; Singleton, N.; Taylor, C. Psychosis and drug dependence: results from a national survey of prisoners Br. J. Psychiatry 2002, 181, 393-398
12. McKetin, R.; Lubman, D. I.; Baker, A. L.; Dawe, S.; Ali, R. L. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study JAMA Psychiatry 2013, 70, 319-324
13. Medhus, S.; Mordal, J.; Holm, B.; Morland, J.; Bramness, J. G. A comparison of symptoms and drug use between patients with methamphetamine associated psychoses and patients diagnosed with schizophrenia in two acute psychiatric wards Psychiatry Res. 2013, 206, 17-21
14. Sato, M. A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis Ann. N.Y. Acad. Sci. 1992, 654, 160-170
15. Lecomte, T.; Mueser, K. T.; MacEwan, W.; Thornton, A. E.; Buchanan, T.; Bouchard, V.; Goldner, E.; Brink, J.; Lang, D.; Kang, S.; Barr, A. M.; Honer, W. G. Predictors of persistent psychotic symptoms in persons with methamphetamine abuse receiving psychiatric treatment J. Nerv. Ment. Dis. 2013, 201, 1085-1089
16. Yui, K.; Ishiguro, T.; Goto, K.; Ikemoto, S. Susceptibility to subsequent episodes in spontaneous recurrence of methamphetamine psychosis Ann. N.Y. Acad. Sci. 2000, 914, 292-302
17. Callaghan, R. C.; Cunningham, J. K.; Allebeck, P.; Arenovich, T.; Sajeev, G.; Remington, G.; Boileau, I.; Kish, S. J. Methamphetamine use and schizophrenia: a population-based cohort study in California Am. J. Psychiatry 2012, 169, 389-396
18. Kittirattanapaiboon, P.; Mahatnirunkul, S.; Booncharoen, H.; Thummawomg, P.; Dumrongchai, U.; Chutha, W. Long-term outcomes in methamphetamine psychosis patients after first hospitalisation Drug Alcohol Rev. 2010, 29, 456-461
19. Ujike, H. Stimulant-induced psychosis and schizophrenia: the role of sensitization Curr. Psychiatry Rep. 2002, 4, 177-184
20. Yui, K.; Goto, K.; Ikemoto, S.; Ishiguro, T.; Angrist, B.; Duncan, G. E.; Sheitman, B. B.; Lieberman, J. A.; Bracha, S. H.; Ali, S. F. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization Mol. Psychiatry 1999, 4, 512-523
21. Pierce, R. C.; Kalivas, P. W. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants Brain Res. 1997, 25, 192-216
22. Sato, M.; Chen, C. C.; Akiyama, K.; Otsuki, S. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis Biol. Psychiatry 1983, 18, 429-440
23. Akiyama, K.; Saito, A.; Shimoda, K. Chronic methamphetamine psychosis after long-term abstinence in Japanese incarcerated patients Am. J. Addict. 2011, 20, 240-249
24. Ohmori, T.; Ito, K.; Abekawa, T.; Koyama, T. Psychotic relapse and maintenance therapy in paranoid schizophrenia: a 15 year follow up Eur. Arch. Psychiatry Clin. Neurosci. 1999, 249, 73-78
25. Olivares, J. M.; Sermon, J.; Hemels, M.; Schreiner, A. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review Ann. Gen. Psychiatry 2013, 12, 32
26. Lieberman, J. A.; Kane, J. M.; Alvir, J. Provocative tests with psychostimulant drugs in schizophrenia Psychopharmacology 1987, 91, 415-433
27. Featherstone, R. E.; Kapur, S.; Fletcher, P. J. The amphetamine-induced sensitized state as a model of schizophrenia Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2007, 31, 1556-1571
28. Anderson, S. W.; Bechara, A.; Damasio, H.; Tranel, D.; Damasio, A. R. Impairment of social and moral behavior related to early damage in human prefrontal cortex Nat. Neurosci 1999, 2, 1032-1037
29. Ridderinkhof, K. R.; van den Wildenberg, W. P. M.; Segalowitz, S. J.; Carter, C. S. Neurocognitive mechanisms of cognitive control: The role of prefrontal cortex in action selection, response inhibition, performance monitoring, and reward-based learning Brain Cognit. 2004, 56, 129-140
30. Minzenberg, M. J.; Laird, A. R.; Thelen, S.; Carter, C. S.; Glahn, D. C. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia Arch. Gen. Psychiatry 2009, 66, 811-822
31. Reichenberg, A.; Harvey, P. D. Neuropsychological impairments in schizophrenia: Integration of performance-based and brain imaging findings Psychol. Bull. 2007, 133, 833-858
32. Mistry, M.; Gillis, J.; Pavlidis, P. Meta-analysis of gene coexpression networks in the post-mortem prefrontal cortex of patients with schizophrenia and unaffected controls BMC Neurosci, 2013, 14, 105
33. Kamei, H.; Nagai, T.; Nakano, H.; Togan, Y.; Takayanagi, M.; Takahashi, K.; Kobayashi, K.; Yoshida, S.; Maeda, K.; Takuma, K.; Nabeshima, T.; Yamada, K. Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice Biol. Psychiatry 2006, 59, 75-84
34. Srisurapanont, M.; Arunpongpaisal, S.; Wada, K.; Marsden, J.; Ali, R.; Kongsakon, R. Comparisons of methamphetamine psychotic and schizophrenic symptoms: A differential item functioning analysis Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2011, 35, 959-964
35. Steketee, J. D. Neurotransmitter systems of the medial prefrontal cortex: potential role in sensitization to psychostimulants Brain Res. Rev. 2003, 41, 203-228
36. Kobeissy, F. H.; Warren, M. W.; Ottens, A. K.; Sadasivan, S.; Zhang, Z.; Gold, M. S.; Wang, K. K. Psychoproteomic analysis of rat cortex following acute methamphetamine exposure J. Proteome Res. 2008, 7, 1971-1983
37. Faure, J. J.; Hattingh, S. M.; Stein, D. J.; Daniels, W. M. Proteomic analysis reveals differentially expressed proteins in the rat frontal cortex after methamphetamine treatment Metab. Brain Dis. 2009, 24, 685-700
38. Morshedi, M.; Meredith, G. Repeated amphetamine administration induces Fos in prefrontal cortical neurons that project to the lateral hypothalamus but not the nucleus accumbens or basolateral amygdala Psychopharmacology 2008, 197, 179-189
39. Iwazaki, T.; McGregor, I. S.; Matsumoto, I. Protein expression profile in the amygdala of rats with methamphetamine-induced behavioral sensitization Neurosci. Lett. 2008, 435, 113-119
40. Harkin, A.; Connor, T. J.; Mulrooney, J.; Kelly, J. P.; Leonard, B. E. Prior exposure to methylenedioxyamphetamine (MDA) induces serotonergic loss and changes in spontaneous exploratory and amphetamine-induced behaviors in rats Life Sci. 2001, 68, 1367-1382
41. Mirzaei, M.; Pascovici, D.; Atwell, B. J.; Haynes, P. A. Differential regulation of aquaporins, small GTPases and V-ATPases proteins in rice leaves subjected to drought stress and recovery Proteomics 2012, 12, 864-877
42. Gammulla, C. G.; Pascovici, D.; Atwell, B. J.; Haynes, P. A. Differential proteomic response of rice (Oryza sativa) leaves exposed to high- and low-temperature stress Proteomics 2011, 11, 2839-2850
43. Neilson, K.; Keighley, T.; Pascovici, D.; Cooke, B.; Haynes, P. Label-free quantitative shotgun proteomics using normalized spectral abundance factors. In Proteomics for Biomarker Discovery; Zhou, M.; Veenstra, T., Eds.; Humana Press: New York, 2013; Vol. 1002; pp 205-222.
44. Ago, Y.; Tanaka, T.; Kita, Y.; Tokumoto, H.; Takuma, K.; Matsuda, T. Lithium attenuates methamphetamine-induced hyperlocomotion and behavioral sensitization via modulation of prefrontal monoamine release Neuropharmacology 2012, 62, 1634-1639
45. Lee, A.; Chick, J. M.; Kolarich, D.; Haynes, P. A.; Robertson, G. R.; Tsoli, M.; Jankova, L.; Clarke, S. J.; Packer, N. H.; Baker, M. S. Liver membrane proteome glycosylation changes in mice bearing an extra-hepatic tumor Mol. Cell. Proteomics 2011, 10, M900538mcp900200
46. Pascovici, D.; Keighley, T.; Mirzaei, M.; Haynes, P. A.; Cooke, B. PloGO: plotting gene ontology annotation and abundance in multi-condition proteomics experiments Proteomics 2012, 12, 406-410
47. Martins-de-Souza, D.; Gattaz, W.; Schmitt, A.; Rewerts, C.; Maccarrone, G.; Dias-Neto, E.; Turck, C. Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259, 151-163
48. Moskvina, V.; Craddock, N.; Holmans, P.; Nikolov, I.; Pahwa, J. S.; Green, E.; Owen, M. J.; O'Donovan, M. C. Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk Mol. Psychiatry 2009, 14, 252-260
49. Shimamoto, C.; Ohnishi, T.; Maekawa, M.; Watanabe, A.; Ohba, H.; Arai, R.; Iwayama, Y.; Hisano, Y.; Toyota, T.; Toyoshima, M.; Suzuki, K.; Shirayama, Y.; Nakamura, K.; Mori, N.; Owada, Y.; Kobayashi, T.; Yoshikawa, T. Functional characterization of FABP3, 5 and 7 gene variants identified in schizophrenia and autism spectrum disorder and mouse behavioral studies Hum. Mol. Genet. 2014, 10.1093/hmg/ddu369
50. Martins-de-Souza, D.; Maccarrone, G.; Wobrock, T.; Zerr, I.; Gormanns, P.; Reckow, S.; Falkai, P.; Schmitt, A.; Turck, C. W. Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia J. Psychiatr. Res. 2010, 44, 1176-1189
51. Minoretti, P.; Politi, P.; Coen, E.; Di Vito, C.; Bertona, M.; Bianchi, M.; Emanuele, E. The T393C polymorphism of the GNAS1 gene is associated with deficit schizophrenia in an Italian population sample Neurosci. Lett. 2006, 397, 159-163
52. Sun, J.; Wan, C.; Jia, P.; Fanous, A. H.; Kendler, K. S.; Riley, B. P.; Zhao, Z. Application of systems biology approach identifies and validates GRB2 as a risk gene for schizophrenia in the Irish Case Control Study of Schizophrenia (ICCSS) sample Schizophr. Res. 2011, 125, 201-208
53. Benitez-King, G.; Ramirez-Rodriguez, G.; Ortiz, L.; Meza, I. The neuronal cytoskeleton as a potential therapeutical target in neurodegenerative diseases and schizophrenia Curr. Drug Targets: CNS Neurol. Disord. 2004, 3, 515-533
54. Smutzer, G.; Lee, V. M.; Trojanowski, J. Q.; Arnold, S. E. Human olfactory mucosa in schizophrenia Ann. Otol., Rhinol., Laryngol. 1998, 107, 349-355
55. Shao, L.; Martin, M. V.; Watson, S. J.; Schatzberg, A.; Akil, H.; Myers, R. M.; Jones, E. G.; Bunney, W. E.; Vawter, M. P. Mitochondrial involvement in psychiatric disorders Ann. Med. 2008, 40, 281-295
56. Martins-de-Souza, D.; Gattaz, W.; Schmitt, A.; Rewerts, C.; Marangoni, S.; Novello, J.; Maccarrone, G.; Turck, C.; Dias-Neto, E. Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis J. Neural Transm. 2009, 116, 275-289
57. Halim, N. D.; Weickert, C. S.; McClintock, B. W.; Hyde, T. M.; Weinberger, D. R.; Kleinman, J. E.; Lipska, B. K. Presynaptic proteins in the prefrontal cortex of patients with schizophrenia and rats with abnormal prefrontal development Mol. Psychiatry 2003, 8, 797-810
58. Ayalew, M.; Le-Niculescu, H.; Levey, D. F.; Jain, N.; Changala, B.; Patel, S. D.; Winiger, E.; Breier, A.; Shekhar, A.; Amdur, R.; Koller, D.; Nurnberger, J. I.; Corvin, A.; Geyer, M.; Tsuang, M. T.; Salomon, D.; Schork, N. J.; Fanous, A. H.; O'Donovan, M. C.; Niculescu, A. B. Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction Mol. Psychiatry 2012, 17, 887-905
59. Taurino, F.; Stanca, E.; Siculella, L.; Trentadue, R.; Papa, S.; Zanotti, F.; Gnoni, A. Mitochondrial proteome analysis reveals depression of the Ndufs3 subunit and activity of complex I in diabetic rat brain J. Proteomics 2012, 75, 2331-2341
60. Senior, A. E. ATP synthesis by oxidative phosphorylation Physiol. Rev. 1988, 68, 177-231
61. Uranova, N.; Orlovskaya, D.; Vikhreva, O.; Zimina, I.; Kolomeets, N.; Vostrikov, V.; Rachmanova, V. Electron microscopy of oligodendroglia in severe mental illness Brain Res. Bull. 2001, 55, 597-610
62. Buchsbaum, M. S.; Hazlett, E. A. Positron emission tomography studies of abnormal glucose metabolism in schizophrenia Schizophr. Bull. 1998, 24, 343-364
63. 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis Neuropsychopharmacology 2005, 30, 1949-1962
64. Prabakaran, S.; Swatton, J. E.; Ryan, M. M.; Huffaker, S. J.; Huang, J.-J.; Griffin, J. L.; Wayland, M.; Freeman, T.; Dudbridge, F.; Lilley, K. S.; Karp, N. A.; Hester, S.; Tkachev, D.; Mimmack, M. L.; Yolken, R. H.; Webster, M. J.; Torrey, E. F.; Bahn, S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress Mol. Psychiatry 2004, 9, 684-697
65. James, R.; Adams, R. R.; Christie, S.; Buchanan, S. R.; Porteous, D. J.; Millar, J. K. Disrupted in Schizophrenia 1 (DISC1) is a multicompartmentalized protein that predominantly localizes to mitochondria Mol. Cell. Neurosci. 2004, 26, 112-122
66. Karry, R.; Klein, E.; Ben Shachar, D. Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study Biol. Psychiatry 2004, 55, 676-684
67. Fattal, O.; Budur, K.; Vaughan, A. J.; Franco, K. Review of the literature on major mental disorders in adult patients with mitochondrial diseases Psychosomatics 2006, 47, 1-7
68. Mancuso, M.; Ricci, G.; Choub, A.; Filosto, M.; DiMauro, S.; Davidzon, G.; Tessa, A.; Santorelli, F. M.; Murri, L.; Siciliano, G. Autosomal dominant psychiatric disorders and mitochondrial DNA multiple deletions: report of a family J. Affective Disord. 2008, 106, 173-177
69. Prayson, R. A.; Wang, N. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS) syndrome: an autopsy report Arch. Pathol. Lab. Med. 1998, 122, 978-981
70. Kasahara, T.; Kubota, M.; Miyauchi, T.; Noda, Y.; Mouri, A.; Nabeshima, T.; Kato, T. Mice with neuron-specific accumulation of mitochondrial DNA mutations show mood disorder-like phenotypes Mol. Psychiatry 2006, 11, 523
71. Theis, M.; Speidel, D.; Willecke, K. Astrocyte cultures from conditional connexin43-deficient mice Glia 2004, 46, 130-141
72. Frisch, C.; Theis, M.; De Souza Silva, M. A.; Dere, E.; Söhl, G.; Teubner, B.; Namestkova, K.; Willecke, K.; Huston, J. P. Mice with astrocyte-directed inactivation of connexin43 exhibit increased exploratory behaviour, impaired motor capacities, and changes in brain acetylcholine levels Eur. J. Neurosci. 2003, 18, 2313-2318
73. Mitterauer, B. Loss of function of glial gap junctions may cause severe cognitive impairments in schizophrenia Med. Hypotheses 2009, 73, 393-397
74. Wang, C. K.; Simon, A.; Jessen, C. M.; Oliveira, C. L. P.; Mack, L.; Braunewell, K.-H.; Ames, J. B.; Pedersen, J. S.; Hofmann, A. Divalent cations and redox conditions regulate the molecular structure and function of visinin-like protein-1 PLoS One 2011, 6, e26793
75. Shioda, N.; Yamamoto, Y.; Watanabe, M.; Owada, Y.; Fukunaga, K. Heart-type fatty acid binding protein regulates dopamine D2 receptor function Neurosci. Res. 2010, 68, e56-e57
76. Fritschy, J.-M.; Panzanelli, P.; Tyagarajan, S. Molecular and functional heterogeneity of GABAergic synapses Cell. Mol. Life Sci. 2012, 69, 2485-2499
77. Wesseling, H.; Chan, M. K.; Tsang, T. M.; Ernst, A.; Peters, F.; Guest, P. C.; Holmes, E.; Bahn, S. A combined metabonomic and proteomic approach identifies frontal cortex changes in a chronic phencyclidine rat model in relation to human schizophrenia brain pathology Neuropsychopharmacology 2013, 38, 2532-2544
78. Hong, K. S.; Won, H.-H.; Cho, E.-Y.; Jeun, H. O.; Cho, S.-S.; Lee, Y.-S.; Park, D. Y.; Jang, Y. L.; Choi, K.-S.; Lee, D.; Kim, M.-J.; Kim, S.; Han, W. S.; Kim, J.-W. Genome-widely significant evidence of linkage of schizophrenia to chromosomes 2p24.3 and 6q27 in an SNP-based analysis of Korean families Am. J. Med. Genet., Part B 2009, 150B, 647-652
79. Bernstein, H.-G.; Becker, A.; Keilhoff, G.; Spilker, C.; Gorczyca, W. A.; Braunewell, K.-H.; Grecksch, G. Brain region-specific changes in the expression of calcium sensor proteins after repeated applications of ketamine to rats Neurosci. Lett. 2003, 339, 95-98
80. Braunewell, K. H.; Dwary, A. D.; Richter, F.; Trappe, K.; Zhao, C.; Giegling, I.; Schonrath, K.; Rujescu, D. Association of VSNL1 with schizophrenia, frontal cortical function, and biological significance for its gene product as a modulator of cAMP levels and neuronal morphology Transl. Psychiatry 2011, 1, e22
81. Seeman, P.; Kapur, S. Schizophrenia: more dopamine, more D2 receptors Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 7673-7675
82. Gee, C. E.; Mansuy, I. M. Protein phosphatases and their potential implications in neuroprotective processes Cell. Mol. Life Sci. 2005, 62, 1120-1130
83. Mumby, M. PP2A: unveiling a reluctant tumor suppressor Cell 2007, 130, 21-24
84. Mansuy, I. M. Calcineurin in memory and bidirectional plasticity Biochem. Biophys. Res. Commun. 2003, 311, 1195-1208
85. + leukemias Cancer Metastasis Rev. 2008, 27, 159-168
86. 2+ dysregulation with brain aging J. Neurosci. 2001, 21, 4066-4073
87. Miyakawa, T.; Leiter, L. M.; Gerber, D. J.; Gainetdinov, R. R.; Sotnikova, T. D.; Zeng, H.; Caron, M. G.; Tonegawa, S. Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 8987-8992
88. Zeng, H.; Chattarji, S.; Barbarosie, M.; Rondi-Reig, L.; Philpot, B. D.; Miyakawa, T.; Bear, M. F.; Tonegawa, S. Forebrain-specific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory Cell 2001, 107, 617-629
89. Saraf, A. Regulation of tyrosine hydroxylase by protein phosphatase 2A. Ph.D. Thesis, University of Iowa, Iowa City, IA, 2008
90. Nishi, A.; Snyder, G. L.; Greengard, P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine J. Neurosci. 1997, 17, 8147-8155
91. Karler, R.; Calder, L. D.; Thai, L. H.; Bedingfield, J. B. A dopaminergic-glutamatergic basis for the action of amphetamine and cocaine Brain Res. 1994, 658, 8-14
92. Wolf, M. E. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants Prog. Neurobiol. 1998, 54, 679-720
93. Hakak, Y.; Walker, J. R.; Li, C.; Wong, W. H.; Davis, K. L.; Buxbaum, J. D.; Haroutunian, V.; Fienberg, A. A. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 4746-4751
94. Gerber, D. J.; Hall, D.; Miyakawa, T.; Demars, S.; Gogos, J. A.; Karayiorgou, M.; Tonegawa, S. Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 8993-8998
95. Liu, Y. L.; Fann, C. S.; Liu, C. M.; Chang, C. C.; Yang, W. C.; Hung, S. I.; Yu, S. L.; Hwang, T. J.; Hsieh, M. H.; Liu, C. C.; Tsuang, M. M.; Wu, J. Y.; Jou, Y. S.; Faraone, S. V.; Tsuang, M. T.; Chen, W. J.; Hwu, H. G. More evidence supports the association of PPP3CC with schizophrenia Mol. Psychiatry 2007, 12, 966-974
96. Albert, K. A.; Hemmings, H. C., Jr.; Adamo, A. I. B.; Potkin, S. G.; Akbarian, S.; Sandman, C. A.; Cotman, C. W.; Bunney, W. E., Jr.; Greengard, P. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia Arch. Gen. Psychiatry 2002, 59, 705-712
97. Asada, H.; Kawamura, Y.; Maruyama, K.; Kume, H.; Ding, R. G.; Kanbara, N.; Kuzume, H.; Sanbo, M.; Yagi, T.; Obata, K. Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 6496-6499
98. Lau, C. G.; Murthy, V. N. Activity-dependent regulation of inhibition via GAD67 J. Neurosci. 2012, 32, 8521-8531
99. Bu, Q.; Lv, L.; Yan, G.; Deng, P.; Wang, Y.; Zhou, J.; Yang, Y.; Li, Y.; Cen, X. NMR-based metabonomic in hippocampus, nucleus accumbens and prefrontal cortex of methamphetamine-sensitized rats Neurotoxicology 2013, 36, 17-23
100. Lewis, D. A. Cortical circuit dysfunction and cognitive deficits in schizophrenia-implications for preemptive interventions Eur. J. Neurosci 2012, 35, 1871-1878
101. Hashimoto, T.; Volk, D. W.; Eggan, S. M.; Mirnics, K.; Pierri, J. N.; Sun, Z.; Sampson, A. R.; Lewis, D. A. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia J. Neurosci. 2003, 23, 6315-6326
102. Guidotti, A.; Auta, J.; Davis, J. M. Decrease in reelin and glutamic acid decarboxylase67 (gad67) expression in schizophrenia and bipolar disorder: A postmortem brain study Arch. Gen. Psychiatry 2000, 57, 1061-1069
103. Varoqueaux, F.; Jamain, S.; Brose, N. Neuroligin 2 is exclusively localized to inhibitory synapses Eur. J. Cell Biol. 2004, 83, 449-456
104. Levinson, J. N.; Chery, N.; Huang, K.; Wong, T. P.; Gerrow, K.; Kang, R.; Prange, O.; Wang, Y. T.; El-Husseini, A. Neuroligins mediate excitatory and inhibitory synapse formation: involvement of PSD-95 and neurexin-1beta in neuroligin-induced synaptic specificity J. Biol. Chem. 2005, 280, 17312-17319
105. Hines, R. M.; Wu, L.; Hines, D. J.; Steenland, H.; Mansour, S.; Dahlhaus, R.; Singaraja, R. R.; Cao, X.; Sammler, E.; Hormuzdi, S. G.; Zhuo, M.; El-Husseini, A. Synaptic imbalance, stereotypies, and impaired social interactions in mice with altered neuroligin 2 expression J. Neurosci. 2008, 28, 6055-6067
106. Blundell, J.; Tabuchi, K.; Bolliger, M. F.; Blaiss, C. A.; Brose, N.; Liu, X.; Sudhof, T. C.; Powell, C. M. Increased anxiety-like behavior in mice lacking the inhibitory synapse cell adhesion molecule neuroligin 2 Genes, Brain Behav. 2009, 8, 114-126
107. Sun, C.; Cheng, M. C.; Qin, R.; Liao, D. L.; Chen, T. T.; Koong, F. J.; Chen, G.; Chen, C. H. Identification and functional characterization of rare mutations of the neuroligin-2 gene (NLGN2) associated with schizophrenia Hum. Mol. Genet. 2011, 20, 3042-3051
108. Gibson, J. R.; Huber, K. M.; Sudhof, T. C. Neuroligin-2 deletion selectively decreases inhibitory synaptic transmission originating from fast-spiking but not from somatostatin-positive interneurons J. Neurosci. 2009, 29, 13883-13897
109. Sohal, V. S.; Zhang, F.; Yizhar, O.; Deisseroth, K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance Nature 2009, 459, 698-702
110. Beasley, C. L.; Reynolds, G. P. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics Schizophr. Res. 1997, 24, 349-355
111. Curley, A. A.; Arion, D.; Volk, D. W.; Asafu-Adjei, J. K.; Sampson, A. R.; Fish, K. N.; Lewis, D. A. Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features Am. J. Psychiatry 2011, 168, 921-929
112. Volman, V.; Behrens, M. M.; Sejnowski, T. J. Downregulation of parvalbumin at cortical GABA synapses reduces network gamma oscillatory activity J. Neurosci. 2011, 31, 18137-18148
113. Massi, L.; Lagler, M.; Hartwich, K.; Borhegyi, Z.; Somogyi, P.; Klausberger, T. Temporal dynamics of parvalbumin-expressing axo-axonic and basket cells in the rat medial prefrontal cortex in vivo J. Neurosci. 2012, 32, 16496-16502
114. Başar, E.; Başar-Eroglu, C.; Karakaş, S.; Schürmann, M. Gamma, alpha, delta, and theta oscillations govern cognitive processes Int. J. Psychophysiol. 2001, 39, 241-248
115. Benchenane, K.; Tiesinga, P. H.; Battaglia, F. P. Oscillations in the prefrontal cortex: a gateway to memory and attention Curr. Opin. Neurobiol. 2011, 21, 475-485
116. Minzenberg, M. J.; Firl, A. J.; Yoon, J. H.; Gomes, G. C.; Reinking, C.; Carter, C. S. Gamma oscillatory power is impaired during cognitive control independent of medication status in first-episode schizophrenia Neuropsychopharmacology 2010, 35, 2590-2599
117. Akbarian, S.; Huang, H. S. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders Brain Res. Rev. 2006, 52, 293-304